satiety: the version I wish someone had shown me in week 1
satiety: the version I wish someone had shown me in week 1. Numbers below. Ask me the boring questions, they are the useful ones.
Kept a log purely because so few people are logging this one. It is one person and it is not data.
Why this compound is not simply another agonist, which is how it gets described everywhere else.
Amylin is co-secreted with insulin and signals satiety through its own receptor complexes. It is a different axis from the incretin system, not a parallel version of it. That is why the combination story is interesting: two mechanisms that address appetite differently, rather than more agonism at one receptor.
It is also why the dosing intuitions people bring from the semaglutide and tirzepatide boards do not transfer. Different receptors, different exposure-response, and no published schedule anybody here can reason from.
I will update this if the picture changes rather than quietly leaving it up.
best — the order this archive was captured in
Dosing intuitions from the GLP-1 boards do not transfer. Different receptor family, different exposure-response, and no published schedule for members to reason from.
Dosing intuitions from the GLP-1 boards do not transfer.
Agreed, and the combination arms are where the interesting numbers actually live.
Agreed, and the combination arms are where the interesting numbers actually live.
noor_hovland is right that the evidence base here is thin. Conclusions should be held loosely.
noor_hovland is right that the evidence base here is thin.
Adding the standing caveat — nothing here is approved standalone and research material is not for human use.
Push back: the evidence base here is thin enough that a confident ranking against the established compounds is not supportable.
do not assume the dosing intuitions from the GLP-1 boards transfer
amylin and GLP-1 are not redundant pathways
Combination and monotherapy arms must be read separately. Efficacy and tolerability both differ substantially between them and summaries routinely blur the two.
Went looking for independent results on this and found a handful across the whole site. That is the honest state of the evidence.
independent purity data on this compound is thin
That is preclinical work and the thread is treating it as a human finding.
Is there any independent purity data on this compound that you have seen?
Which trial and which readout?